Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
OncoTherapy Science FCF Yield % Related Terms
OncoTherapy Science FCF Yield % Historical Data
* Premium members only.
The historical data trend for OncoTherapy Science's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4564 vs VRTX, REGN, RVMD: FCF Yield % Comparison
For the Biotechnology subindustry, OncoTherapy Science's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OncoTherapy Science FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OncoTherapy Science's FCF Yield % distribution charts can be found below:
* The bar in red indicates where OncoTherapy Science's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OncoTherapy Science (TSE:4564) has a FCF Yield % of -11.49 as of Aug. 23, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on OncoTherapy Science and its competitors. According to the industry distribution chart, OncoTherapy Science ranks #782 out of 1410 companies in the Biotechnology industry, placing it in the top 55.5%.
Is OncoTherapy Science's FCF Yield % too high?
OncoTherapy Science's current FCF Yield % is -11.49. Based on the distribution chart, OncoTherapy Science ranks #782 out of 1410 companies in the Biotechnology industry, which is below the industry midpoint. Overall, OncoTherapy Science has a GF Score™ of 51/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does OncoTherapy Science's FCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, OncoTherapy Science ranks #782 out of 1410 companies for FCF Yield %. This places OncoTherapy Science in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on OncoTherapy Science and its competitors. OncoTherapy Science's current FCF Yield % is -11.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoTherapy Science stock overvalued right now?
Based on GuruFocus' analysis, OncoTherapy Science (TSE:4564) is currently considered Modestly Overvalued. The stock's GF Value™ is 円18.19, compared to a current price of 円21.00 — trading 15.4% above its estimated fair value. The current FCF Yield % is -11.49. OncoTherapy Science's overall GF Score™ is 51/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For OncoTherapy Science (TSE:4564), the current FCF Yield % is -11.49 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OncoTherapy Science (TSE:4564) Overvalued in 2026?
Based on GuruFocus' analysis, OncoTherapy Science stock appears to be overvalued.
The current stock price of 円21.00 is trading 15.4% above its estimated GF Value™ of 円18.19.
GuruFocus considers OncoTherapy Science to be Modestly Overvalued.
Key valuation signals for TSE:4564:
FCF Yield %: -11.49
GF Value™: 円18.19 vs. price of 円21.00 (15.4% above fair value)
No single metric tells the full story. See the TSE:4564 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OncoTherapy Science Inc focuses on cancer-related cells and genes and develops cancer therapy products which include low molecular drugs, antibody drugs, cancer peptide vaccine, and diagnostic medicine in Japan.
51GF Score
Get the complete analysis for TSE:4564
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4564 has been successfully added to your 
